CG Oncology, Inc., a California corporation originally formed on September 24, 2010, was subsequently re-registered as a Delaware corporation on November 30, 2017. The Company is a late-stage clinical biopharmaceutical company focused on the development and commercialization of cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for the treatment of bladder cancer. Its clinical programs target high-risk and intermediate-risk non-muscle invasive bladder cancer patients with limited treatment options. 

CGON

CGON Profile